According to this document, drugs on the list of medicines permitted for centralized public procurement must meet one of the following criteria:
- Drugs are used by national programs, projects or units;
- Drugs meet all of the following criteria:
+ Drugs are on the list of medicines permitted for tendering and not on the list of medicines permitted for application of the price negotiation approach;
+ Drugs are used at great value or in large quantities by healthcare establishments nationwide;
+ Drugs have obtained at least 03 certificates of registration for marketing authorization from at least 03 pharmaceutical manufacturers meeting technical requirements prescribed in Clause 1 and 2 of Article 7 in the Circular No. 15/2019/TT-BYT.
The list of medicines permitted for centralized public procurement must be made after making sure that the volume of these drugs are adequate to be supplied after winning bids, and the list will not adversely impact domestic pharmaceutical manufacturers in general.
The Circular No. 15/2020/TT-BYT is entering into force on October 6, 2020.
>> CLICK HERE TO READ THE ARTICLE IN VIETNAMESE
1.282